Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Structure and Assembly

Nuclear Export of Human Immunodeficiency Virus Type 1 Vpr Is Not Required for Virion Packaging

Yonchu Jenkins, Patricia V. Sanchez, Barbara E. Meyer, Michael H. Malim
Yonchu Jenkins
Departments of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia V. Sanchez
Departments of Microbiology and
Cell and Molecular Biology Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6148
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara E. Meyer
Departments of Microbiology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Malim
Departments of Microbiology and
Medicine and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.75.17.8348-8352.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The human immunodeficiency virus type 1 Vpr protein is both packaged into virions and efficiently localized to the nucleus. In this report, we show that a significant fraction of Vpr also accumulates in the cytoplasm of virus-producing cells. Although Vpr shuttles between the nucleus and the cytoplasm, studies with an export-deficient Vpr mutant reveal that nuclear export is not required for virion incorporation.

The ∼15-kDa human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr is efficiently packaged into progeny virions (4, 25, 32). Although other accessory proteins, namely, Vif (3, 9, 20, 23) and Nef (31, 43), are also found in virus particles, the levels of incorporated Vpr appear to be considerably higher. Indeed, recent studies have shown that the ratio of Vpr to Gag in virions is ∼1:7 (29), whereas ratios in the order of ∼1:50 have been reported for Vif to Gag (3, 9, 23). In terms of the sequence determinants of Vpr packaging, a leucine-rich element in the p6 region of the p55Gag polyprotein and a region of Vpr that overlaps a predicted α-helical domain (residues 16 to 33) have each been found to be critical (5, 21, 24, 26).

Vpr is present early in HIV-1 infection as a component of postentry nucleoprotein complexes (frequently called preintegration complexes [PICs]) (12, 18) and is also expressed late in infection as the product of a Rev-dependent transcript (14). Two main functions that directly impact the HIV-1 replicative cycle, one of which is dependent on virion incorporation, have been attributed to Vpr. In the first function, Vpr enhances HIV-1 infectivity by stimulating the nuclear import of PICs (11, 18), an effect that is presumably mediated by the karyophilic properties of Vpr associated with these complexes (7, 42). In the second, Vpr that is expressed in infected cells that are proliferating induces their arrest at the G2/M boundary (17, 19, 35, 36). It has been suggested that this helps to maximize virion production because the viral long terminal repeat promoter is most active during the G2 phase of the cell cycle (15, 16).

Vpr, in the absence of other viral proteins, has been shown to localize efficiently to the nucleus (5, 7, 25). Given this strong karyophilic potential, it is unclear how Vpr becomes incorporated into progeny virus particles that assemble in the cytoplasm (13). To address this issue, we used two independent methods to examine the subcellular localization of Vpr in the absence or presence of the other viral proteins. Initially, HeLa cell monolayers were transiently transfected with either the Vpr expression vector pCMV/Vpr or the full-length proviral vector pYU-2 (7). At 48 h, the cells were subjected to indirect immunofluorescence using Vpr- or Gag-specific antibodies (Fig.1). As previously demonstrated, transfection with pCMV/Vpr alone resulted in the marked nuclear localization of Vpr (Fig. 1a). In contrast, substantial accumulation of Vpr in the cytoplasm was observed when expression was in the context of the provirus (Fig. 1b). Consistent with previous work, Gag was detected only in the cytoplasm (Fig. 1c).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Subcellular localization of Vpr in the absence or presence of viral proteins. HeLa cell monolayers (35-mm diameter) were transiently transfected with either the pcDNA1-based wild-type Vpr expression vector pCMV/Vpr (a) or an expression vector containing the HIV-1YU-2 provirus (b and c) (8). At 48 h, cells were fixed and analyzed by indirect immunofluorescence using a Vpr-specific monoclonal antibody, followed by a fluorescein isothiocyanate-conjugated secondary antibody. Gag was detected using a p24Gag-specific antiserum raised in rabbits, followed by a Texas red-conjugated secondary antibody (41). Samples were photographed at a magnification of ×400 using a Nikon Microphot-SA microscope attached to a charge-coupled device camera.

We next used a membrane flotation assay, in which cell extracts are overlaid with a discontinuous sucrose gradient and the ability of a protein of interest to ascend the gradient during centrifugation is used as a measure of its association with membranes (30). Cytoplasmic extracts were prepared from HeLa cells transfected with either pCMV/Vpr or a full-length provirus expression vector. Samples were then subjected to flotation through a 65% sucrose layer, and the gradient fractions were analyzed for the presence of Vpr or Gag by immunoprecipitation followed by Western blotting (Fig.2). As expected, Vpr alone did not appear to be membrane associated and was detected only in fractions from the bottom of the gradient (Fig. 2A, lanes 8 to 11). However, in cells cotransfected with the provirus, a significant proportion of Vpr was found in membrane-containing fractions at the top of the gradient (Fig.2B, lane 3). A significant percentage of total Gag protein was also detected in this region of the gradient; this percentage presumably represents Gag that is being assembled into progeny virions at the plasma membrane.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Association of Vpr with membranes in HIV-1-infected cells. A total of 4 × 107 HeLa cells were transiently transfected with pCMV/Vpr (A), a wild-type provirus expression vector (B), or a proviral vector containing a disrupted p6Gagregion (the 44LF→PS mutation) (1) (C). At 48 h, cells were fractionated into nuclear and cytoplasmic compartments by treatment with 0.01% digitonin, followed by Dounce homogenization. Samples were centrifuged at 2,000 × g to pellet the nuclei, and the supernatants were concentrated to ∼600 μl using a Centricon Plus 5-kDa nominal molecular weight limit centrifuge filter, mixed with 90% sucrose to yield a final sucrose concentration of 70%, and then processed as described previously (30). Gradient fractions were analyzed for Vpr or Gag by immunoprecipitation using specific antisera raised in rabbits and by Western blotting using a polyclonal Vpr-specific mouse antiserum or a p24Gag-specific monoclonal antibody (41). Bound antibodies were visualized using horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence.

These experiments revealed that a significant proportion of HIV-1 Vpr is cytoplasmic in the context of virus-producing cells. This diminution in the efficiency of nuclear accumulation presumably facilitates the packaging of Vpr into virions. Vpr that is cytoplasmic could be derived from two nonexclusive sources: nuclear Vpr could be exported to the cytoplasm, or newly translated Vpr could be precluded from entering the nucleus by retention in the cytoplasm.

Since Vpr is both nuclear and cytoplasmic in provirus-transfected HeLa cells (Fig. 1b), the possibility that nuclear Vpr can undergo export to the cytoplasm was evaluated using transient interspecies heterokaryons (Fig. 3a to c) (28). Here, proteins that have the ability to enter and exit the nucleus (called shuttle proteins) rapidly redistribute between multiple nuclei that have been manipulated to share a common cytoplasm. HeLa cells that had been transfected with pCMV/Vpr (donor cells) were therefore fused to nonexpressing murine L cells (acceptor cells) using polyethylene glycol and cultured for 2 h in the presence of cycloheximide to prevent further translation. Cells were then fixed and double labeled using a Vpr-specific monoclonal antibody (Fig. 3a) and a DNA dye, Hoechst 33258, that stains L nuclei with a signature punctate pattern (Fig. 3b) and thereby distinguishes them from the donor nuclei. As seen in Fig.3a, Vpr rapidly and efficiently accumulated in the L acceptor nuclei, thus defining HIV-1 Vpr as a nucleocytoplasmic shuttle protein.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

HIV-1 Vpr is a nucleocytoplasmic shuttle protein. HeLa cells were transfected with the wild-type expression vector pCMV/Vpr (a to c and g to i) or its mutated derivative pCMV/VprL68A (d to f). At 24 h, the cells were trypsinized and overlaid onto mouse L cells previously plated on glass coverslips. After the HeLa cells had settled, the coverslips were washed with phosphate-buffered saline (PBS) and inverted onto polyethylene glycol (Sigma P-7181) to initiate cell-to-cell fusion. After ∼100 s, the coverslips were washed gently with PBS, placed into fresh medium containing 50 μg of cycloheximide/ml, and incubated at 37°C for 2 h in the absence (a to f) or presence (g to i) of 5 nM LMB. Samples were fixed and then subjected to indirect immunofluorescence using a Vpr-specific monoclonal antibody, followed by a fluorescein isothiocyanate-conjugated secondary antibody. Before mounting, cell nuclei were stained using Hoechst 33258 (Molecular Probes), followed by a PBS wash. The corresponding phase-contrast images of the heterokaryons are shown in panels c, f, and i. For the Rev controls (j and k), HeLa cells were transfected with a vector that expresses a Rev-green fluorescent protein (GFP) fusion, maintained for 48 h, incubated for 3 h in medium containing 50 μg of cycloheximide/ml and 5 μg of actinomycin D (Act. D)/ml in the absence or presence of 5 nM LMB, and then fixed and mounted. W/T, wild type.

The nuclear export of proteins, like protein nuclear import, is usually mediated by specific peptide sequences that engage nuclear transport receptors (27). In the case of export, these targeting signals are called nuclear export signals (NESs) and are commonly rich in hydrophobic amino acids such as leucine. Among our collection of mutated vpr alleles are a number that encode missense mutants where leucine residues are replaced with other amino acids. To test whether any of these mutant proteins are debilitated for nuclear export, heterokaryon assays were performed using HeLa and L cells as described above. The results for one of the mutants, where the leucine at position 68 has been exchanged for alanine (L68A), are shown in Fig.3d to f. Unlike wild-type Vpr, the L68A protein failed to accumulate in the L nuclei, demonstrating that the leucine at position 68 is essential for the nuclear export function of Vpr. Similar results were obtained using Vpr encoded by a T-cell line-adapted virus, HIV-1IIIB, and with mutant Vpr proteins in which the leucines at positions 64, 67, and 68 were all replaced with alanine (data not shown).

Prototypic leucine-rich NESs, such as that contained in the HIV-1 Rev protein (34), confer nuclear export through binding to the export receptor CRM1; importantly, both binding and export are sensitive to inhibition by the fungal metabolite leptomycin B (LMB) (6, 10). Because leucine 68 is in a region of Vpr that contains several other leucines as well as additional hydrophobic residues, we assessed the sensitivity of Vpr shuttling to inhibition by LMB using the heterokaryon assay. Addition of 5 nM LMB to heterokaryons containing wild-type Vpr had no inhibitory effect on the extent of shuttling (Fig. 3g to i). Control samples expressing a Rev-green fluorescent protein fusion that had been relocalized to the cytoplasm by treatment with 5 μg of actinomycin D/ml (Fig. 3j) (28) confirmed that LMB efficiently inhibited leucine-rich NES-mediated export in our hands (Fig. 3k). The lack of susceptibility of Vpr export to LMB suggests that its export mechanism may differ from that used by classical leucine-rich NESs. For instance, Vpr may utilize CRM1 in an unconventional manner (22) or may achieve export through a CRM1-independent mechanism. Either way, LMB resistance is perhaps not surprising, given the lack of evident sequence alignment between the NES consensus sequence and the region of Vpr that includes residue 68 (Fig. 4).

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

Organization of 97-amino-acid HIV-1YU-2 Vpr. The amino acid sequence neighboring the leucine at position 68 is shown in the context of a Vpr secondary structure profile predicted by the program PHDsec (37-39); the regions of predicted α-helix are indicated in gray. A consensus leucine-rich NES sequence derived in vivo (2) is shown below the Vpr sequence for comparison. Relatively conserved hydrophobic residues are boxed in gray, X denotes any amino acid, and λ represents amino acid residues with bulky hydrophobic side chains.

Having found that HIV-1 Vpr shuttles and that the L68A mutation blocks export, we were in a position to address whether virion packaging is dependent on nuclear export. 293T monolayers were therefore cotransfected with pYU-2/Δvpr and hemagglutinin (HA)-tagged versions of pCMV/Vpr or pCMV/VprL68A. At 24 h, virions were pelleted from culture supernatants by centrifugation at 100,000 × g for 90 min and analyzed by Western blotting for Gag and Vpr content in parallel with the corresponding whole-cell lysates. As seen in Fig. 5, wild-type Vpr and the L68A mutant were incorporated into virions with comparable efficiencies (lanes 3 and 4). The lower level of packaged L68A is most likely a consequence of reduced accumulation in the 293T producer cells (compare lane 1 to lane 2), a phenomenon that is frequently observed for mutant Vpr proteins (5). In sum, HIV-1 Vpr can be incorporated into progeny virions irrespective of nuclear export.

Fig. 5.
  • Open in new tab
  • Download powerpoint
Fig. 5.

Nuclear export of Vpr is not required for virion packaging. A total of 107 293T cells were cotransfected with pYU-2/Δvpr and vectors containing HA-tagged versions of wild-type Vpr, pCMV/HA-Vpr, or the L68A mutant pCMV/HA-VprL68A. At 24 h, viral supernatants were clarified by centrifugation and filtered through a 0.45-μm-pore-size membrane and virions were pelleted through a 20% sucrose cushion by ultracentrifugation at 100,000 × g for 90 min. The transfected cells (lanes 1 and 2) and pelleted virions (lanes 3 and 4) were resuspended in loading buffer and resolved in parallel by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Vpr and Gag were detected by Western blotting using the HA-specific monoclonal antibody HA.11 (Covance) and a p24Gag-specific monoclonal antibody, respectively, and by enhanced chemiluminescence. W/T, wild type.

In order for Vpr packaging to occur, newly translated Vpr must be retargeted away from the nucleus and towards the cytoplasmic site(s) of virus assembly and budding. In light of Vpr's ability to interact with p6Gag (1, 40) and the essential role of the leucine-rich region of p6 in Vpr packaging (21, 24), we wished to determine if this Gag sequence also mediated the cytoplasmic retention of Vpr in HIV-1-infected cells. To address this, a p6 mutant provirus expression vector was constructed such that the critical leucine and phenylalanine residues at positions 44 and 45 (1, 21) were exchanged for proline and serine. Using transfected cells and the same membrane flotation assay employed earlier, we found that Vpr accumulated in cytoplasmic membrane-containing fractions with an efficiency that closely matched that seen for the wild-type virus (Fig. 2, compare panels B and C). Thus, the retention of Vpr in the cytoplasm of virus-producing cells is not mediated solely through an interaction with the leucine-rich element of Gag. Whether cytoplasmic accumulation is dictated by other regions of Gag, other viral proteins, or as an indirect consequence of HIV-1 gene expression in host cells remains to be determined.

Finally, our observations also raise the question, what is the biological significance of Vpr shuttling? Although resolution of this issue awaits further experimentation, it is tempting to speculate that the nucleocytoplasmic movement of Vpr, like that of many cellular regulators of the cell cycle (33, 44), may relate to the ability of Vpr to influence normal cell cycle progression.

ACKNOWLEDGMENTS

We thank Minoru Yoshida for the generous gift of LMB, David Rekosh and Marie-Louise Hammarskjöld for important reagents, and Laurie Zimmerman for excellent secretarial support.

This work was supported by U.S. Public Health Service grants AI46942 (M.H.M.), AI09996 (Y.J.), and GM18907 (P.V.S.).

FOOTNOTES

    • Received 18 December 2000.
    • Accepted 30 May 2001.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Bachand F.,
    2. Yao X. J.,
    3. Hrimech M.,
    4. Rougeau N.,
    5. Cohen E. A.
    Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor.J. Biol. Chem. 274 1999 9083 9091
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bogerd H. P.,
    2. Fridell R. A.,
    3. Benson R. E.,
    4. Hua J.,
    5. Cullen B. R.
    Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay.Mol. Cell. Biol. 16 1996 4207 4214
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Camaur D.,
    2. Trono D.
    Characterization of human immunodeficiency virus type 1 Vif particle incorporation.J. Virol. 70 1996 6106 6111
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Cohen E. A.,
    2. Dehni G.,
    3. Sodroski J. G.,
    4. Haseltine W. A.
    Human immunodeficiency virus vpr product is a virion-associated regulatory protein.J. Virol. 64 1990 3097 3099
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Di Marzio P.,
    2. Choe S.,
    3. Ebright M.,
    4. Knoblauch R.,
    5. Landau N. R.
    Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr.J. Virol. 69 1995 7909 7916
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Fornerod M.,
    2. Ohno M.,
    3. Yoshida M.,
    4. Mattaj I. W.
    CRM1 is an export receptor for leucine-rich nuclear export signals.Cell 90 1997 1051 1060
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Fouchier R. A. M.,
    2. Meyer B. E.,
    3. Simon J. H. M.,
    4. Fischer U.,
    5. Albright A. V.,
    6. González-Scarano F.,
    7. Malim M. H.
    Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex.J. Virol. 72 1998 6004 6013
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Fouchier R. A. M.,
    2. Meyer B. E.,
    3. Simon J. H. M.,
    4. Fischer U.,
    5. Malim M. H.
    HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.EMBO J. 16 1997 4531 4539
    OpenUrlAbstract
  9. 9.↵
    1. Fouchier R. A. M.,
    2. Simon J. H. M.,
    3. Jaffe A. B.,
    4. Malim M. H.
    Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins.J. Virol. 70 1996 8263 8269
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Fukuda M.,
    2. Asano S.,
    3. Nakamura T.,
    4. Adachi M.,
    5. Yoshida M.,
    6. Yanagida M.,
    7. Nishida E.
    CRM1 is responsible for intracellular transport mediated by the nuclear export signal.Nature 390 1997 308 311
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Gallay P.,
    2. Stitt V.,
    3. Mundy C.,
    4. Oettinger M.,
    5. Trono D.
    Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.J. Virol. 70 1996 1027 1032
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Gallay P.,
    2. Swingler S.,
    3. Song J.,
    4. Bushman F.,
    5. Trono D.
    HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.Cell 83 1995 569 576
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Garnier L.,
    2. Bowzard J. B.,
    3. Wills J. W.
    Recent advances and remaining problems in HIV assembly.AIDS 12 (suppl.) 1998 S5 S16
    OpenUrl
  14. 14.↵
    1. Garrett E. D.,
    2. Tiley L. S.,
    3. Cullen B. R.
    Rev activates expression of the human immunodeficiency virus type1 vif and vpr gene products.J. Virol. 65 1991 1653 1657
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Goh W. C.,
    2. Rogel M. E.,
    3. Kinsey C. M.,
    4. Michael S. F.,
    5. Fultz P. N.,
    6. Nowak M. A.,
    7. Hahn B. H.,
    8. Emerman M.
    HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.Nat. Med. 4 1998 65 71
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Gummuluru S.,
    2. Emerman M.
    Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines.J. Virol. 73 1999 5422 5430
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. He J.,
    2. Choe S.,
    3. Walker R.,
    4. Di Marzio P.,
    5. Morgan D. O.,
    6. Landau N. R.
    Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.J. Virol. 69 1995 6705 6711
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Heinzinger N. K.,
    2. Bukrinsky M. I.,
    3. Haggerty S. A.,
    4. Ragland A. M.,
    5. Kewalramani V.,
    6. Lee M.-A.,
    7. Gendelman H. E.,
    8. Ratner L.,
    9. Stevenson M.,
    10. Emerman M.
    The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.Proc. Nat. Acad. Sci. USA 91 1994 7311 7315
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Jowett J. B. M.,
    2. Planelles V.,
    3. Poon B.,
    4. Shah N. P.,
    5. Chen M.-L.,
    6. Chen I. S. Y.
    The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.J. Virol. 69 1995 6304 6313
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Karczewski M. K.,
    2. Strebel K.
    Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.J. Virol. 70 1996 494 507
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Kondo E.,
    2. Göttlinger H. G.
    A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.J. Virol. 70 1996 159 164
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Künzler M.,
    2. Gerstberger T.,
    3. Stutz F.,
    4. Bischoff F. R.,
    5. Hurt E.
    Yeast Ran-binding protein 1 (Yrb1) shuttles between the nucleus and cytoplasm and is exported from the nucleus via a CRM1 (XPO1)-dependent pathway.Mol. Cell. Biol. 20 2000 4295 4308
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Liu H.,
    2. Wu X.,
    3. Newman M.,
    4. Shaw G. M.,
    5. Hahn B. H.,
    6. Kappes J. C.
    The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.J. Virol. 69 1995 7630 7638
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Lu Y.-L.,
    2. Bennett R. P.,
    3. Wills J. W.,
    4. Gorelick R.,
    5. Ratner L.
    A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.J. Virol. 69 1995 6873 6879
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Lu Y.-L.,
    2. Spearman P.,
    3. Ratner L.
    Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions.J. Virol. 67 1993 6542 6550
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Mahalingam S.,
    2. Ayyavoo V.,
    3. Patel M.,
    4. Kieber-Emmons T.,
    5. Weiner D. B.
    Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.J. Virol. 71 1997 6339 6347
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Mattaj I. W.,
    2. Englmeier L.
    Nucleocytoplasmic transport: the soluble phase.Annu. Rev. Biochem. 67 1998 265 306
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Meyer B. E.,
    2. Malim M. H.
    The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm.Genes Dev. 8 1994 1538 1547
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Müller B.,
    2. Tessmer U.,
    3. Schubert U.,
    4. Kräusslich H.-G.
    Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells.J. Virol. 74 2000 9727 9731
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Paillart J.-C.,
    2. Göttlinger H. G.
    Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of Gag membrane targeting.J. Virol. 73 1999 2604 2612
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Pandori M. W.,
    2. Fitch N. J. S.,
    3. Craig H. M.,
    4. Richman D. D.,
    5. Spina C. A.,
    6. Guatelli J. C.
    Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.J. Virol. 70 1996 4283 4290
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Paxton W.,
    2. Connor R. I.,
    3. Landau N. R.
    Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.J. Virol. 67 1993 7229 7237
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Pines J.
    Four-dimensional control of the cell cycle.Nat. Cell Biol. 1 1999 E73 E79
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Pollard V. W.,
    2. Malim M. H.
    The HIV-1 Rev protein.Annu. Rev. Microbiol. 52 1998 491 532
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Re F.,
    2. Braaten D.,
    3. Franke E. K.,
    4. Luban J.
    Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2 -cyclin B.J. Virol. 69 1995 6859 6864
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Rogel M. E.,
    2. Wu L. I.,
    3. Emerman M.
    The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.J. Virol. 69 1995 882 888
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Rost B.,
    2. Sander C.
    Combining evolutionary information and neural networks to predict protein secondary structure.Proteins 19 1994 55 72
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Rost B.,
    2. Sander C.
    Prediction of protein secondary structure at better than 70% accuracy.J. Mol. Biol. 232 1993 584 599
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Rost B.,
    2. Sander C.,
    3. Schneider R.
    PHD—an automatic mail server for protein secondary structure prediction.Comput. Appl. Biosci. 10 1994 53 60
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Selig L.,
    2. Pages J.-C.,
    3. Tanchou V.,
    4. Prévéral S.,
    5. Berlioz-Torrent C.,
    6. Liu L. X.,
    7. Erdtmann L.,
    8. Darlix J.-L.,
    9. Benarous R.,
    10. Benichou S.
    Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses.J. Virol. 73 1999 592 600
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Simon J. H. M.,
    2. Fouchier R. A. M.,
    3. Southerling T. E.,
    4. Guerra C. B.,
    5. Grant C. K.,
    6. Malim M. H.
    The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells.J. Virol. 71 1997 5259 5267
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Vodicka M. A.,
    2. Koepp D. M.,
    3. Silver P. A.,
    4. Emerman M.
    HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection.Genes Dev. 12 1998 175 185
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Welker R.,
    2. Kottler H.,
    3. Kalbitzer H. R.,
    4. Krausslich H. G.
    Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase.Virology 219 1996 228 236
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Yang J.,
    2. Kornbluth S.
    All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners.Trends Cell Biol. 9 1999 207 210
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Nuclear Export of Human Immunodeficiency Virus Type 1 Vpr Is Not Required for Virion Packaging
Yonchu Jenkins, Patricia V. Sanchez, Barbara E. Meyer, Michael H. Malim
Journal of Virology Sep 2001, 75 (17) 8348-8352; DOI: 10.1128/JVI.75.17.8348-8352.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear Export of Human Immunodeficiency Virus Type 1 Vpr Is Not Required for Virion Packaging
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Nuclear Export of Human Immunodeficiency Virus Type 1 Vpr Is Not Required for Virion Packaging
Yonchu Jenkins, Patricia V. Sanchez, Barbara E. Meyer, Michael H. Malim
Journal of Virology Sep 2001, 75 (17) 8348-8352; DOI: 10.1128/JVI.75.17.8348-8352.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Cell Nucleus
Gene Products, vpr
HIV-1
virion
virus assembly

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514